TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy

Area of Science:

• Nephrology
• Molecular Biology
• Pathology

Background:

• Renal fibrosis, a hallmark of progressive kidney disease, involves dysregulated matrix turnover.
• Proteolytic machinery impairment contributes to the accumulation of extracellular matrix in kidneys.
• Tissue inhibitor of metalloproteinases-1 (TIMP-1) plays a role in regulating matrix metalloproteinases (MMPs).

Purpose of the Study:

• To investigate the role of TIMP-1 deficiency in attenuating interstitial fibrosis.
• To determine if genetic absence of TIMP-1 impacts fibrosis development following unilateral ureteral obstruction (UUO).

Main Methods:

• Comparison of wild-type (Timp-1) and TIMP-1-deficient (timp-1) mice subjected to UUO or sham operations.
• Assessment of renal fibrosis markers, including collagen content and interstitial area staining.
• Quantification of mRNA levels for TIMP-1, MMP-9, TIMP-3, and plasminogen activator inhibitor-1.
• Evaluation of myofibroblast numbers and gene expression related to fibrogenesis.

Main Results:

• TIMP-1 mRNA levels significantly increased post-UUO in wild-type mice.
• MMP-9 activity decreased in all UUO groups but remained higher in timp-1 mice.
• Interstitial fibrosis severity, collagen content, and fibrogenic gene expression were similar between Timp-1 and timp-1 groups.
• TIMP-3 and plasminogen activator inhibitor-1 mRNA levels were elevated in TIMP-1-deficient mice after UUO.

Conclusions:

• Elimination of TIMP-1 alone does not significantly alter the severity of interstitial renal fibrosis.
• Compensatory upregulation of other protease inhibitors (e.g., TIMP-2, TIMP-3, PAI-1) may mitigate the absence of TIMP-1.
• Inhibition of intrinsic MMP activity might not be a critical profibrotic event in the kidney.